Distinct bone marrow morphologic features discriminate myelodysplastic syndromes patients with and without an early platelet response to decitabine

Annette M May; Julia Stomper; Tina E Joeckel; Peter Bronsert; Pierre W Wijermans; Martin Werner; Michael Lübbert

doi:10.1111/bjh.16615

Distinct bone marrow morphologic features discriminate myelodysplastic syndromes patients with and without an early platelet response to decitabine

Br J Haematol. 2020 Jun;189(5):e194-e197. doi: 10.1111/bjh.16615. Epub 2020 Mar 24.

Authors

Annette M May^{1

2}, Julia Stomper^{2

3}, Tina E Joeckel^{2

3}, Peter Bronsert^{1

2

4}, Pierre W Wijermans⁵, Martin Werner^{1

2

4

6}, Michael Lübbert^{2

3

6}

Affiliations

¹ Institute for Surgical Pathology, Medical Center - University of Freiburg, Freiburg, Germany.
² Faculty of Medicine, University of Freiburg, Freiburg, Germany.
³ Division of Hematology, Oncology and Stem Cell Transplantation, Department of Medicine, University of Freiburg Medical Center, Freiburg, Germany.
⁴ Tumorbank, Comprehensive Cancer Center Freiburg, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
⁵ HagaZiekenhuis, The Hague, The Netherlands.
⁶ German Consortium for Translational Cancer Research, Freiburg, Germany.

PMID: 32207144
DOI: 10.1111/bjh.16615

No abstract available

Keywords: decitabine; early platelet response; megakaryocytes; myelodysplastic syndrome.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antimetabolites / therapeutic use*
Biopsy
Bone Marrow / pathology*
Decitabine / therapeutic use*
Humans
Megakaryocytes / pathology
Myelodysplastic Syndromes / drug therapy*
Myelodysplastic Syndromes / pathology
Platelet Count
Time Factors
Treatment Outcome

Substances

Antimetabolites
Decitabine

Publication types

MeSH terms

Substances

Grants and funding